Study Finds Viread Advantages in Black Patients An analysis of two Gilead-sponsored studies suggests that black HIV-positive patients have a better chances of an undetectable viral load after 96 weeks using treatment regimens containing Viread compared to those containing the thymidine analogues Retrovir or Zerit.
